Globus Medical To Merge With NuVasive In $3.1Bn All-Stock Deal Analysts Foresee Challenges
Executive Summary
Analysts from Piper Sandler and BTIG noted that the proposed merger between Globus Medical and NuVasive raises concerns about cultural fit, approach to commercialization and profitability, as well as anti-trust issues.
You may also be interested in...
NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients
This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.
Getting Personal With Tom Miller: CEO Turned VC On Ethical Bets In Diagnostics
Medtech Insight talked to GreyBird Ventures founder Tom Miller about his investment philosophy, ethical filter in selecting diagnostics-focused start-ups, the future of diagnostics such as at-home home-testing and AI, and his life-long passion for motocross racing.
Medtech DEI Experts Talk Shop: ‘It’s Going To Transform Businesses’
An all-female panel of medtech DEI leaders at the LSX Congress USA conference discussed the importance of diversity and inclusion in research, clinical trials, product development and services to advance health equity as well as fundamental business goals.